€0.486 surge: CYAD.BR (EURONEXT) Celyad Oncology +38% on high volume, Feb 2026

Celyad Oncology’s CYAD.BR stock jumped to €0.486 on 20 Feb 2026, rising +38.07% on a volume surge to 451,024 shares. The move made CYAD.BR stock one of today’s high-volume movers on EURONEXT and pushed price well above its 50-day average of €0.19. Traders reacted to clinical and funding optics, while technicals show a strong short-term trend and elevated momentum. We flag the spike for active traders and long-term investors watching upcoming catalysts and the March earnings window.

Price action and volume: CYAD.BR stock

CYAD.BR stock closed at €0.486, up €0.13 or 38.07% from the previous close of €0.352. The session high was €0.49 and the low was €0.35, showing intra-day volatility. Volume hit 451,024 versus an average volume of 49,349, a relative volume of 9.14, confirming institutional or block interest rather than a thin uptick.

Catalysts and news driving the move

Trading appears driven by renewed clinical focus on Celyad’s CAR-T candidates and a tighter funding outlook for small biotech names in Europe. The company lists an upcoming earnings announcement on 2026-03-19, which can reprice sentiment. Market participants cited pipeline milestones and licensing reminders tied to past agreements with larger partners.

Fundamentals and valuation snapshot for CYAD.BR stock

Celyad Oncology (EURONEXT) is a clinical-stage biotech with market cap €21,754,286.00 and 44,761,905 shares outstanding. Reported EPS is -2.21 and PE is negative at -0.22, reflecting recurring R&D losses. Key ratios: current ratio 0.66, price to sales ≈111.90, and cash per share €0.02. These metrics underline high risk, capital needs, and a valuation driven by pipeline potential rather than earnings.

Technical read: momentum and trend metrics

Technicals support the breakout: RSI 64.22, MACD histogram positive, and ADX 45.03 signalling a strong trend. Bollinger bands show a move above the middle band (€0.23) toward the upper band (€0.41), while ATR is €0.05 indicating elevated volatility. Momentum indicators imply short-term strength but an overbought Money Flow Index at 87.50 warns of quick pullbacks.

Meyka AI rates CYAD.BR with a score out of 100: grade and model forecast

Meyka AI rates CYAD.BR with a score out of 100: 73.58 (Grade B+, Suggestion: BUY). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of €0.33 and a yearly price of €0.17455. Versus the current price €0.486, the yearly projection implies a model-based downside of -64.07%. Forecasts are model-based projections and not guarantees.

Price targets, scenario planning and sector context

Given volatility and clinical risk, a scenario range helps. Our view: bull target €0.90 on positive trial news, base target €0.50 if sentiment holds, and bear target €0.15 if funding or negative data emerges. The Healthcare biotech sector in Europe shows mixed YTD performance; small-cap drug developers remain high beta, and CYAD.BR stock will likely track sector sentiment and news flow closely.

Final Thoughts

Today’s spike in CYAD.BR stock to €0.486 on volume 451,024 flags a meaningful short-term repricing for Celyad Oncology on EURONEXT. The move is supported by strong technicals (RSI 64.22, ADX 45.03) but sits against weak fundamentals: EPS -2.21, current ratio 0.66, and high price-to-sales multiple. Meyka AI’s model projects a yearly level near €0.17455, implying model-based downside of -64.07% from today’s price, while our scenario targets range from €0.15 (bear) to €0.90 (bull). Active traders may watch momentum and volume for follow-through; longer-term investors should prioritise clinical readouts and cash runway before adding exposure. Remember, Meyka AI is an AI-powered market analysis platform; its grades and forecasts are model outputs, not guarantees or financial advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.